does pfizer have a glp-1 drug weight loss available for pre-order in China Pfizer Accelerates Obesity Pipeline with
Description
Abstract Obesity is a major public health crisis
Weber, M
Retrospective database studies suggest that adherence and persistence rates with once-weekly injectable GLP-1 receptor agonists are better than those achieved with more frequently dosed treatments (5356)
Safety Considerations Most common adverse effects: Nausea Vomiting Diarrhea GI intolerance Rare but important: Pancreatitis Gallbladder disease Potential thyroid C-cell concerns in animal models Careful patient selection and dose titration remain essential
But you need to understand that every medication is different
